Thursday Dec 5
Stemline Therapeutics, Inc. To Present At The Oppenheimer 24th Annual Healthcare Conference
Stemline Therapeutics, Inc. announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Oppenheimer 24th Annual Healthcare Conference on Wednesday, December 11, 2013 at 7:45 AM ET.
Stemline rallies after outlining results from additional vaccine study
Stemline Therapeutics enjoys a strong session after announcing late Friday evening that the results of a clinical trial of SL-701 in low-grade glioma were being presented at a Meeting of the World Federation of Neuro-Oncology.
Companies Advancing Stem Cell Therapies Could Also Advance Your Portfolio Dollars
Stem cell therapies are becoming mainstream. From giant pharmaceutical companies like Baxter International , which is conducting a Phase III clinical trial using its CD34+ stem cells derived from a patient's own bone marrow to treat myocardial Ischemia, to small startups like Stemline Therapeutics developing treatments to target cancer stem cells, ... (more)
Stemline Therapeutics Announces the Presentation of Clinical Trial...
Stemline Therapeutics, Inc. announced today that clinical trial results of a synthetic peptide vaccine for brain cancer, now being developed as SL-701, will be presented by investigators from the University of Pittsburgh at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology being held in conjunction with the 18th Annual Society ... (more)
Stemline Therapeutics Stock Rating Reaffirmed by Aegis
's stock had its "buy" rating restated by research analysts at Aegis in a report released on Wednesday, AnalystRatingsNetwork.com reports.